Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results of phase II trial GORTEC 2008-03.
Joel Guigay
Consultant or Advisory Role - Merck Serono; Sanofi
Honoraria - Merck Serono
Research Funding - Chugai Pharma; Merck Serono; Novartis; Sanofi
Jerome Fayette
No relevant relationships to disclose
Anne-Francoise Dillies
No relevant relationships to disclose
Christian Sire
No relevant relationships to disclose
Joseph N. Kerger
No relevant relationships to disclose
Isabelle Tennevet
No relevant relationships to disclose
Jean-Pascal H. Machiels
Consultant or Advisory Role - Boehringer Ingelheim; Genmab; Merck Serono
Research Funding - Merck Serono; Novartis
Sylvie Zanetta
No relevant relationships to disclose
Yoann Pointreau
No relevant relationships to disclose
Laurence Bozec Le Moal
No relevant relationships to disclose
Lydia Brugel Ribere
No relevant relationships to disclose
Stefanie Henry
No relevant relationships to disclose
Stéphane Temam
No relevant relationships to disclose